# Open-label Extension of the HOPE-2 Trial

> **NCT04428476** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Capricor Inc.** · enrollment: 13 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **BIOLOGICAL:** Deramiocel (CAP-1002)

## Key facts

- **NCT ID:** NCT04428476
- **Lead sponsor:** Capricor Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-05
- **Primary completion:** 2022-02-16
- **Final completion:** 2026-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428476, "Open-label Extension of the HOPE-2 Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04428476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*